Janux Therapeutics (JANX) FCF Margin (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of FCF Margin data on file, last reported at 337.8% in Q1 2026.

• FCF Margin for Q1 2026 came in at 337.8%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 571.56% (down 7102.0% YoY), and the FY2025 annual result was 832.78%, down 41558.0% from the prior year.
• FCF Margin declined to 337.8% in Q1 2026 per JANX's latest filing, from 121.13% in the prior quarter.
• Over five years, FCF Margin peaked at 115.92% in Q2 2024 and troughed at 1440.78% in Q2 2023.
• A 5-year average of 587.56% and a median of 464.0% in 2023 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2022 and 2024: FCF Margin sank 221293 bps in 2022, then soared 132486 bps in 2024.
• A 5-year view of FCF Margin shows it stood at 491.0% in 2022, then increased by 21 bps to 390.21% in 2023, then fell by 16 bps to 451.25% in 2024, then jumped by 73 bps to 121.13% in 2025, then slumped by 179 bps to 337.8% in 2026.
• Business Quant data shows JANX's FCF Margin at 337.8% in Q1 2026, 121.13% in Q3 2025, and 451.25% in Q3 2024.